ArticleClinical drug investigation2026

Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial.

Jiyeon Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.